Departments of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India.
The Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan, USA.
Neuropsychobiology. 2024;83(2):101-113. doi: 10.1159/000538348. Epub 2024 May 14.
The brain-derived neurotrophic factor (BDNF) and transcription nuclear factor erythroid 2-related factor-2 (NRF-2) play an important role in Alzheimer's disease (AD). However, the interactive involvement of BDNF and NRF-2 in respect to antioxidant mechanisms in different parts of the AD brain is still unclear. Considering the above condition, used S-nitrosoglutathione (GSNO) to examine whether it modulates the BDNF and NRF-2 levels to activate signaling pathway to promote antioxidant levels in AD brains.
AD was induced by intracerebroventricular infusion of streptozotocin (ICV-STZ, 3 mg/kg) in Wistar rats. The effect of GSNO was analyzed by evaluating the retention of memory in months 1, 2, and 3. After the behavior study, rats were sacrificed and accessed the amyloid beta (Aβ)-40, Aβ42, glutathione (GSH), BDNF, and NRF-2 levels in the hippocampus, cortex, and amygdala tissue.
Pretreatment with GSNO (50 µg/kg/intraperitoneal/day) restored the BDNF, and NRF-2 levels toward normalcy as compared with ICV-STZ + saline-treated animals. Also, GSNO treatment reversed the oxidative stress and increased the GSH levels toward normal levels. Further, reduced Aβ levels and neuronal loss in different brain regions. As a result, GSNO treatment improved the cognitive deficits in ICV-STZ-treated rats.
The results showed that endogenous nitric oxide donor GSNO improved the cognitive deficits and ICV-STZ-induced AD pathological conditions, possibly via attenuating the oxidative stress. Hence, the above finding supported that GSNO treatment may activate BDNF and NRF-2 antioxidant signaling pathways in the AD brain to normalize oxidative stress, which is the main causative factor for ICV-STZ-induced AD pathogenesis.
脑源性神经营养因子(BDNF)和转录核因子红细胞 2 相关因子 2(NRF-2)在阿尔茨海默病(AD)中发挥着重要作用。然而,BDNF 和 NRF-2 在 AD 大脑不同部位的抗氧化机制中的相互作用仍不清楚。鉴于上述情况,本研究使用 S-亚硝基谷胱甘肽(GSNO)来研究其是否可以调节 BDNF 和 NRF-2 水平,以激活信号通路,从而提高 AD 大脑中的抗氧化水平。
通过向 Wistar 大鼠脑室内注射链脲佐菌素(ICV-STZ,3mg/kg)来诱导 AD。通过评估第 1、2 和 3 个月的记忆保留来分析 GSNO 的作用。行为研究后,处死大鼠并检测海马体、皮质和杏仁核组织中的淀粉样β(Aβ)-40、Aβ42、谷胱甘肽(GSH)、BDNF 和 NRF-2 水平。
与 ICV-STZ+生理盐水处理的动物相比,GSNO(50μg/kg/腹腔/天)预处理使 BDNF 和 NRF-2 水平恢复正常。此外,GSNO 处理还逆转了氧化应激并使 GSH 水平恢复正常。进一步降低了不同脑区的 Aβ 水平和神经元丢失。因此,GSNO 处理改善了 ICV-STZ 处理大鼠的认知缺陷。
结果表明,内源性一氧化氮供体 GSNO 通过减轻氧化应激改善了认知缺陷和 ICV-STZ 诱导的 AD 病理状况,可能通过激活 BDNF 和 NRF-2 抗氧化信号通路来实现。因此,上述发现支持 GSNO 治疗可能会激活 AD 大脑中的 BDNF 和 NRF-2 抗氧化信号通路,以纠正氧化应激,这是 ICV-STZ 诱导 AD 发病机制的主要原因。